Equity Overview
Price & Market Data
Price: $0.95
Daily Change: +$0.163 / 17.17%
Range: $0.781 - $1.22
Market Cap: $16,719,107
Volume: 24,055,837
Performance Metrics
1 Week: 51.08%
1 Month: -13.73%
3 Months: -19.39%
6 Months: -31.70%
1 Year: -39.66%
YTD: -14.48%
Company Details
Employees: 21
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic drug candidate is REYOBIQ, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.